← Leaderboards
Gregory P. Bisson
University Of Pennsylvania
$13,346,066
Attributed
$21,400,609
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,400,609 · 10
By mechanism
R01$13,569,923 · 4
UH3$4,733,613 · 1
R21$1,234,764 · 3
UH2$1,199,999 · 1
K23$662,310 · 1
Top collaborators
- Sara Auld6 shared
- Tawanda Gumbo5 shared
- Daniel Kalman5 shared
- Deepak Kaushal5 shared
- Mark A Sellmyer1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- David Rosenthal$1,493,810
- Rahim R Rizi$49,177,138
- Megan L Matthews$2,535,999
- Ronen Marmorstein$40,497,435
- Arijitt Borthakur$976,404
Others in their field
Top investigators on “Pulmonary Tuberculosis”
- Deepak Kaushal · University Of Chicago$31,528,218
- Samuel M Behar · Brigham And Women'S Hospital$23,915,590
- Marcus Aaron Horwitz · University Of California San Francisco$19,937,339
- Shabaana A. Khader · University Of Chicago$19,810,166
- Padmini Salgame · Rutgers Biomedical And Health Sciences$14,763,458
- Susan E Dorman · Johns Hopkins University$13,675,621
Research focus
Pulmonary TuberculosisTuberculosisCessation Of LifeMycobacterium TuberculosisImmune ResponseAdultHiv InfectionsCommunicable DiseasesFutureImmuneResponsePathogenPathway InteractionsPharmaceutical PreparationsHiv-1Immune FunctionSputumCause Of DeathAntiretroviral TherapyLungTuberculosis TreatmentHeterogeneityRestorationImmunologics
Grant awards (33)
Excess cardiovascular inflammation in TB and HIV: EXFIN-TB$2,513,201
R01 · FY2025 · HL · contact PI
Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study$750,208
R01 · FY2025 · AI
Fibroblast activating protein PET-CT imaging of TB-associated fibrosis$446,875
R21 · FY2025 · AI · contact PI
Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study$335,986
R01 · FY2025 · AI
Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study$1,079,424
R01 · FY2024 · AI
Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study$1,120,842
R01 · FY2023 · AI
Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study$962,133
R01 · FY2022 · AI
Development of Gleevec for TB and TB/HIV$1,571,205
UH3 · FY2019 · AI
Rapid Immune Restoration and Lung Injury in HIV/TB$664,038
R01 · FY2019 · AI · contact PI
Development of Gleevec for TB and TB/HIV$1,534,659
UH3 · FY2018 · AI
Rapid Immune Restoration and Lung Injury in HIV/TB$714,852
R01 · FY2018 · AI · contact PI
Development of Gleevec for TB and TB/HIV$1,627,749
UH3 · FY2017 · AI
Rapid Immune Restoration and Lung Injury in HIV/TB$618,851
R01 · FY2017 · AI · contact PI
Rapid Immune Restoration and Lung Injury in HIV/TB$614,410
R01 · FY2016 · AI · contact PI
Development of Gleevec for TB and TB/HIV$599,999
UH2 · FY2016 · AI
Rapid Immune Restoration and Lung Injury in HIV/TB$651,351
R01 · FY2015 · AI · contact PI
Development of Gleevec for TB and TB/HIV$600,000
UH2 · FY2015 · AI
Immune Activation and Isoniazid Metabolism in HIV/TB$206,473
R21 · FY2014 · AI · contact PI
Immune-based detection of rifampicin-resistance in HIV/TB$157,500
R21 · FY2014 · AI · contact PI
Immune Activation and Isoniazid Metabolism in HIV/TB$246,256
R21 · FY2013 · AI · contact PI
Immune-based detection of rifampicin-resistance in HIV/TB$177,660
R21 · FY2013 · AI · contact PI
Immunology and Outcomes after HAART in HIV/TB Coinfection$175,693
R01 · FY2013 · AI · contact PI
Immunology and Outcomes after HAART in HIV/TB Coinfection$975,640
R01 · FY2012 · AI · contact PI
Immunology and Outcomes after HAART in HIV/TB Coinfection$41,446
R01 · FY2012 · AI · contact PI
Immunology and Outcomes after HAART in HIV/TB Coinfection$771,364
R01 · FY2011 · AI · contact PI
Immunology and Outcomes after HAART in HIV/TB Coinfection$676,454
R01 · FY2010 · AI · contact PI
Immunology and Outcomes after HAART in HIV/TB Coinfection$162,418
R01 · FY2010 · AI · contact PI
Immunology and Outcomes after HAART in HIV/TB Coinfection$741,612
R01 · FY2009 · AI · contact PI
Effect of GBV-C on HIV$132,462
K23 · FY2008 · AI · contact PI
Effect of GBV-C on HIV$132,462
K23 · FY2007 · AI · contact PI
Effect of GBV-C on HIV$132,462
K23 · FY2006 · AI · contact PI
Effect of GBV-C on HIV$132,462
K23 · FY2005 · AI
Effect of GBV-C on HIV$132,462
K23 · FY2004 · AI